Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2016 Filed Dec 27, 2016 20:27 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 2,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,957 F1 · kind: Represents a gift to Mercatus Center, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F1 · price: Represents a gift to Mercatus Center, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 00:23 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 34,400 | $61.71 | $2,122,824.00 |
DisclosureSEC source: 0001140361-16-089443 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,007 F1 · kind: The transaction represents a gift to the Farrell Family Foundation, a 501(c)(3) non-profit corporation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.18 to $62.24. The price reported above represents the weighted average sales price. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:49 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-088907 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:49 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $59.83 | $1,196,540.00 |
DisclosureSEC source: 0001140361-16-088907 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,407 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 59.59 to 60.05. The price reported above represents the weighted average sales price. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:49 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-16-088907 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:50 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,365 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-16-088908 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,010 Underlying: ResMed Common Stock · 6,365 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:50 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,365 | $60.00 | $381,900.00 |
DisclosureSEC source: 0001140361-16-088908 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:50 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,365 | $27.58 | $175,546.70 |
DisclosureSEC source: 0001140361-16-088908 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 02:53 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087152 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,407 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 02:19 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087151 · doc1.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,645 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 01:58 UTC |
PACE GARY WDirector
|
GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087150 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 01:53 UTC |
WAREHAM JOHN PDirector
|
GrantResMed Common Stock Options · Derivative | 23,277 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087149 · doc1.xml · derivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 Underlying: ResMed Commmon Stock · 23,277 shares Expires 2023-11-16 F1 · derivative.exercise_date: Options vest in full on the first November 11 following the grant date, or the first annual shareholders meeting following grant date. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 01:52 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock Options · Derivative | 40,736 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087148 · doc1.xml · derivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,736 Underlying: ResMed Common Stock · 40,736 shares Expires 2023-11-16 F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2017, 2018 and 2019. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 01:21 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087147 · doc1.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,649 F1 · shares: Shares awarded are restricted stock units. The RSUs cliff vest on the earlier of November 11, 2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 00:19 UTC Amendment |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087138 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,316 F2 · date: Corrects transaction date previously submitted. F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 23:54 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 37,244 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087135 · doc1.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,244 Underlying: ResMed Common Stock · 37,244 shares Expires 2023-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2017, 2018 and 2019. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 16:15 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 139,665 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087167 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,665 Underlying: ResMed Common Stock · 139,665 shares Expires 2023-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2017, 2018 and 2019. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 16:13 UTC |
ROBERTS CHRISTOPHER GDirector
|
GrantResMed Common Stock Options · Derivative | 23,277 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001140361-16-087166 · doc1.xml · derivative · entry 5 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 Underlying: ResMed Common Stock · 23,277 shares Expires 2023-11-16 F1 · derivative.exercise_date: Options vest in full on the first November 11 following the grant date, or the first annual shareholders meeting following grant date. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 19:09 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,140 | $59.85 | $68,229.00 |
DisclosureSEC source: 0001140361-16-086279 · doc1.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,896 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 19:09 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,194 | $59.85 | $71,460.90 |
DisclosureSEC source: 0001140361-16-086279 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,036 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 19:09 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,043 | $59.85 | $62,423.55 |
DisclosureSEC source: 0001140361-16-086279 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,273 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/13/2013. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:51 UTC |
Reiser AnnePresident - ResMed Europe
|
Tax withholdingResMed Common Stock | 2,247 | $59.85 | $134,482.95 |
DisclosureSEC source: 0001140361-16-086062 · doc1.xml · nonDerivative · entry 3 Reiser Anne · CIK 0001544561 · President - ResMed Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,429 F4 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:51 UTC |
Reiser AnnePresident - ResMed Europe
|
Tax withholdingResMed Common Stock | 2,356 | $59.85 | $141,006.60 |
DisclosureSEC source: 0001140361-16-086062 · doc1.xml · nonDerivative · entry 2 Reiser Anne · CIK 0001544561 · President - ResMed Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,677 F3 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:51 UTC |
Reiser AnnePresident - ResMed Europe
|
Tax withholdingResMed Common Stock | 1,899 | $59.85 | $113,655.15 |
DisclosureSEC source: 0001140361-16-086062 · doc1.xml · nonDerivative · entry 1 Reiser Anne · CIK 0001544561 · President - ResMed Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,033 F1 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/13/2013. F2 · balance_after: Includes 220 shares of ResMed stock purchased on 10/31/2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 8,518 | $59.85 | $509,802.30 |
DisclosureSEC source: 0001140361-16-086061 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,450 F4 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 8,685 | $59.85 | $519,797.25 |
DisclosureSEC source: 0001140361-16-086061 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,968 F3 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 15:50 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 6,469 | $59.85 | $387,169.65 |
DisclosureSEC source: 0001140361-16-086061 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,653 F1 · shares: Disposition to issuer for tax withholding upon vesting of performance-based Restricted Stock Units granted on 11/13/2013. F2 · balance_after: Includes 316 shares of ResMed stock purchased on 10/31/2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 18:01 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 854 | $59.85 | $51,111.90 |
DisclosureSEC source: 0001140361-16-086732 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,490 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 18:01 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 1,789 | $59.85 | $107,071.65 |
DisclosureSEC source: 0001140361-16-086732 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,344 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 18:01 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 1,503 | $59.85 | $89,954.55 |
DisclosureSEC source: 0001140361-16-086732 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,133 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/13/2013. F2 · balance_after: Includes 123 shares of ResMed stock purchased on 10/31/2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 17:57 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 4,082 | $59.85 | $244,307.70 |
DisclosureSEC source: 0001140361-16-086731 · doc1.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,864 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014 Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 17:57 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 3,576 | $59.85 | $214,023.60 |
DisclosureSEC source: 0001140361-16-086731 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,946 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/13/2013. F3 · balance_after: Includes 218 shares of ResMed stock purchased on 10/31/2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2016 Filed Nov 17, 2016 23:53 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087134 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,316 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:16 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-085037 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:16 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $57.28 | $1,145,560.00 |
DisclosureSEC source: 0001140361-16-085037 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,978 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 56.92 to 57.44. The price reported above represents the weighted average sales price. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:16 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-16-085037 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:40 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,033 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-084988 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 6,033 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:40 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,033 | $57.79 | $348,647.07 |
DisclosureSEC source: 0001140361-16-084988 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,273 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $57.73 to $57.81. The price reported above reflects the weighted average sale price. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:40 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,033 | $33.70 | $203,312.10 |
DisclosureSEC source: 0001140361-16-084988 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 212 shares of ResMed stock purchased on October, 31 2016, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 19, 2016 Filed Oct 24, 2016 16:27 UTC |
ROBERTS CHRISTOPHER GDirector
|
GrantResMed Common Stock Options · Derivative | 36,000 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001140361-16-083348 · doc1.xml · derivative · entry 5 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 36,000 shares Expires 2016-12-17 F2 · derivative.exercise_date: Options vest in full (a) on the first Nov. 11 following the grant date or (b) the first annual shareholder's meeting following grant date. Read SEC document |
| October 19, 2016 Filed Oct 24, 2016 16:27 UTC |
ROBERTS CHRISTOPHER GDirector
|
Exercise / conversionResMed Common Stock | 36,000 | $25.54 | $919,440.00 |
DisclosureSEC source: 0001140361-16-083348 · doc1.xml · nonDerivative · entry 1 ROBERTS CHRISTOPHER G · CIK 0001186112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise options and hold shares acquired through purchase. F1 · shares: Exercise options and hold shares acquired through purchase. Read SEC document |
| October 18, 2016 Filed Oct 20, 2016 00:09 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 1,967 | $64.71 | $127,284.57 |
DisclosureSEC source: 0001140361-16-083103 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,513 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 00:13 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,264 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001140361-16-083021 · doc1.xml · derivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,812 Underlying: ResMed Common Stock · 5,264 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest ? per year. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 00:13 UTC |
Hollingshead JamesPresident, Americas
|
SaleResMed Common Stock | 5,264 | $64.43 | $339,159.52 |
DisclosureSEC source: 0001140361-16-083021 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,480 F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 00:13 UTC |
Hollingshead JamesPresident, Americas
|
Exercise / conversionResMed Common Stock | 5,264 | $43.63 | $229,668.32 |
DisclosureSEC source: 0001140361-16-083021 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule10b5-1 Plan. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 19:49 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,975 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-082981 · doc1.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: ResMed Commmon Stock · 5,975 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 19:49 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,975 | $64.25 | $383,869.85 |
DisclosureSEC source: 0001140361-16-082981 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,806 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.15 to $64.43. The price reported above reflects the weighted average sale price. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 19:49 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,975 | $33.70 | $201,357.50 |
DisclosureSEC source: 0001140361-16-082981 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 2,967 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · derivative · entry 7 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 2,967 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 948 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · derivative · entry 6 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,085 Underlying: ResMed Common Stock · 948 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.